

# DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma

Rong-Jie Fu<sup>1</sup>, Wei He<sup>2</sup>, Xiao-Bo Wang<sup>3</sup>, Lei Li<sup>3</sup>, Huan-Bin Zhao<sup>3</sup>, Xiao-Ye Liu<sup>1</sup>, Zhi Pang<sup>3</sup>, Guo-Qiang Chen<sup>1,3</sup>, Lei Huang<sup>\*,3</sup> and Ke-Wen Zhao<sup>\*,3</sup>

Clear cell renal cell carcinoma (ccRCC) is the major subtype of renal cell carcinoma (RCC) that is resistant to conventional radiation and chemotherapy. It is a challenge to explore effective therapeutic targets and drugs for this kind of cancer. Transcription factor Krüppel-like factor 5 (KLF5) exerts diverse functions in various tumor types. By analyzing cohorts of the Cancer Genome Atlas (TCGA) data sets, we find that KLF5 expression is suppressed in ccRCC patients and higher level of KLF5 expression is associated with better prognostic outcome. Our further investigations demonstrate that *KLF5* genomic loci are hypermethylated at proximal exon 4 and suppression of DNA methyltransferase 1 (DNMT1) expression by ShRNAs or a methylation inhibitor 5-Aza-CdR can recover KLF5 expression. Meanwhile, there is a negative correlation between expressions of KLF5 and DNMT1 in ccRCC tissues. Ectopic KLF5 expression inhibits ccRCC cell proliferation and migration/invasion *in vitro* and decreases xenograft growth and metastasis *in vivo*. Moreover, 5-Aza-CdR, a chemotherapy drug as DNMTs' inhibitor that can induce KLF5 expression, suppresses ccRCC cell growth, while knockdown of KLF5 abolishes 5-Aza-CdR-induced growth inhibition. Collectively, our data demonstrate that KLF5 inhibits ccRCC growth as a tumor suppressor and highlight the potential of 5-Aza-CdR to release KLF5 expression as a therapeutic modality for the treatment of ccRCC.

*Cell Death and Disease* (2017) 8, e2952; doi:10.1038/cddis.2017.323; published online 27 July 2017

Renal cell carcinoma (RCC), with the high incidence occurring in developed countries, is the most frequent form of kidney cancer.<sup>1</sup> RCC arises from the proximal renal tubular epithelium of kidneys and accounts for about 85% of renal cancers. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, accounting for 70–75% of cases.<sup>2</sup> Owing to the higher expression of multidrug resistance genes, therapeutic options for ccRCC are limited. To date, the main approach for ccRCC is complete or partial nephrectomy combined with chemotherapy and radiotherapy. Other therapies, including immunotherapy with interleukin-2 (IL-2) or interferon alpha (IFN $\alpha$ ), have been demonstrated low efficiency because of systemic toxicities during ccRCC treatment.<sup>3–5</sup> Therefore, further discoveries of effective therapeutic targets and drugs are paramount to improve the prognosis of ccRCC patients.

DNA methylation is an epigenetic process in which adds a methyl group to the cytosine ring at CpG dinucleotides. It has an important role in the regulation of gene expression through interfering with transcriptional factors binding to DNA, recruiting methyl-CpG-binding proteins to repress DNA transcription and affecting histone modifications and chromatin structure. It has been widely investigated that alterations of DNA methylation, especially hypermethylation of tumor suppressor genes, mediate tumorigenesis.<sup>6</sup> The Cancer Genome Atlas (TCGA)

Project has revealed that increasing hypermethylation frequency is correlated with advanced tumor stage in ccRCC.<sup>7</sup> DNA methylation is mainly facilitated by DNA methyltransferase (DNMT) 1, DNMT3A and DNMT3B.<sup>8</sup> Li *et al.* demonstrated that DNMT1, DNMT3A and DNMT3B expression were significantly higher in ccRCC tissues compared with non-tumor tissues.<sup>9</sup> These findings further confirm the important roles of DNA methylation in ccRCC progression. Decitabine (Dacogen), the clinical form of DNMTs inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR), has been an approved therapy for the treatment of hematological malignancies, as myelodysplastic syndrome and acute myeloid leukemia (AML). Moreover, decitabine is used in treatment of some solid tumors combined with other drugs.<sup>10–12</sup> Hagiwara *et al.*<sup>13</sup> found that 5-Aza-CdR could suppress Caki-1 (a human metastatic RCC cell line) growth *in vivo*. Negrotto *et al.*<sup>14</sup> illuminated low dose 5-Aza-CdR treatment could be a potential non-cytotoxic therapy for RCC. Hence, epigenetic treatment with 5-Aza-CdR seems to be a promising therapeutic regimen for ccRCC.

Krüppel-like factor 5 (KLF5) belongs to Krüppel-like transcription factors family, of which 17 members have been identified.<sup>15,16</sup> KLF5 widely expresses in different tissues and has essential roles in various physiological and pathological processes including cell cycle, angiogenesis, migration, apoptosis, inflammation, self-renew and differentiation.<sup>17</sup>

<sup>1</sup>Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), University of Chinese Academy of Sciences, Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China; <sup>2</sup>Department of Pathology, Ren-Ji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China and <sup>3</sup>Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China

\*Corresponding author: L Huang or K-W Zhao, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, No.280 Chong-Qing South Road, Shanghai, China. Tel: +86 21 63846590-776403; Fax: +86 21 64154900; E-mail: leihuang@shsmu.edu.cn or zkewen@shsmu.edu.cn

Received 16.2.17; revised 27.5.17; accepted 08.6.17; Edited by Y Shi

Notably, it has been reported that *KLF5* is overexpressed in some types of human cancers, like breast and bladder cancer, in which it promotes cancer cells proliferation, metastasis and angiogenesis.<sup>18,19</sup> Whereas, it has also been demonstrated that *KLF5* is deleted or downregulated in other human cancer types such as prostate cancer and AML, in which it inhibits tumor growth and promotes differentiation.<sup>20,21</sup> Thus, *KLF5* functions as an oncogene or a tumor suppressor due to its cellular and genetic context-dependent regulation of target genes.<sup>22,23</sup> In kidney and its collecting system, *KLF5* was reported to express in the collecting duct epithelium and mice with specific deletion of *KLF5* in the collecting duct exerted enhanced interstitial fibrosis after unilateral ureteral obstruction (UUO).<sup>24</sup> Chen *et al.* reported that increasing the matrix stiffness in cultured mouse proximal tubular epithelium cells (mPTECs) could up-regulate *KLF5* expression, which promoted mPTECs proliferation.<sup>25</sup> These data indicate that *KLF5* involves in regulation of renal fibrosis progression under inflammation conditions. It is very interesting to analyze whether *KLF5* has a functional role in ccRCC tumorigenesis and progression. Hence, we analyze online database, clinical patient samples and multiple ccRCC cell lines to uncover the potential role of *KLF5* in ccRCC.

## Results


***KLF5* is significantly downregulated in ccRCC.** To explore whether members of KLF family involve in tumorigenesis of ccRCC, the expression levels of *KLF1-17* genes were analyzed in Oncomine, GEO and TCGA KIRC data sets, respectively. Compared with normal people, it was particularly noteworthy that *KLF5* was significantly and consistently inhibited in ccRCC among the KLF genes across the three data sets analyses (Figures 1a and b; Supplementary Figure 1). Further analysis of TCGA data sets revealed that higher expression level of *KLF5* was associated with better prognostic outcome (Figure 1c). Overall survival rate of ccRCC patients with high *KLF5* expression was significantly higher than patients with low *KLF5* expression, especially after about 7 years (2500 days). These analyses indicated that *KLF5* might be a tumor suppressor in ccRCC. To confirm these findings, protein levels of *KLF5* were detected by immunohistochemistry (IHC) in clinical ccRCC tumors and adjacent normal tissues from Ren-Ji Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and the related clinical information of these patients were shown (Supplementary Table 1). Protein levels of *KLF5* were dramatically reduced in tumor areas than in adjacent normal renal tubule tissues (Figure 1d). Moreover, *KLF5* expression was tested in different ccRCC cell lines and immortal embryonic kidney HEK-293T cells. *KLF5* expression was distinctly inhibited in ccRCC cell lines compared with that in HEK-293T (Figure 1e). These results suggested that *KLF5* might negatively influence the process of ccRCC.

**Hypermethylation suppresses *KLF5* expression in ccRCC.** Subsequently, we investigated how *KLF5* was downregulated in ccRCC. It is well known that inactivation of the tumor suppressor gene Von Hippel-Lindau (*VHL*),

including deletion, mutation and hypermethylation, is an archetypical tumor-initiating event in ccRCC, which leads to constitutive activation HIF- $\alpha$  that promotes tumorigenesis.<sup>26</sup> To investigate whether *VHL* loss resulted in *KLF5* suppression in ccRCC, *VHL* expression was detected in ccRCCs and HEK-293T cells. *VHL* could be detected in Caki-1 and HEK-293T cells, but not in 786-O, RCC4 and A498 cells (Supplementary Figure 2A). A ShRNA specifically against *VHL* was stably infected into *VHL*-expressed Caki-1 and HEK-293T cells, separately. Meanwhile, *VHL* was ectopically expressed in *VHL*-null 786-O, RCC4 and A498 cells. We found that *KLF5* expression was inhibited no matter over-expression or inhibition *VHL* expression (Supplementary Figures 2B and C), which suggested that *KLF5* suppression was not associated with *VHL* deficiency in ccRCC cells.

DNA hypermethylation is a common mechanism for deregulation of tumor suppressor genes. Then, methylation alterations of CpG loci in *KLF5* gene were analyzed on DNA methylation array of TCGA KIRC data sets. Among the detected methylated loci in *KLF5* gene, the methylation level of eleven methylated loci (a-k) increased in ccRCC patients compared with normal people (Figures 2A and B). Five of these methylated loci located in low-methylated area whose methylation value  $\leq 0.3$  (Figures 2B, a-e) and the other six loci located in high-methylated area whose methylation value  $> 0.7$  (Figures 2B, f-k). To validate our findings in TCGA KIRC methylation array, methylation levels of genomic DNA of 786-O cells were analyzed. 786-O cells were treated with or without 5-Aza-CdR, a DNA methylation inhibitor which has been used in clinical cancer therapy. Bisulfite sequencing was then applied to examine the methylation levels of selected methylated loci in *KLF5* gene, of which two loci (Figures 2B, d,e) located at low-methylated area and three loci located at high-methylated area (Figures 2B, i-k) in TCGA methylation analyses. Consistent with TCGA results, methylation levels of five chosen methylated loci (Figures 2B, d,e,i-k) in low and high-methylated area were verified (Figure 2C), and 5-Aza-CdR treatment decreased methylation levels in high-methylated area of 786-O cells. Intriguingly, another fifteen CpG dinucleotides, including two (1/3) in low-methylated area and thirteen (1/3/5/6/7/8/9/10/12/13/14/15/16) in high-methylated area, were confirmed as new methylated loci that not reported in TCGA analyses (Figure 2C). These data suggested that *KLF5* gene was hypermethylated in ccRCC cells. To further investigate the correlation between hypermethylation and *KLF5* expression, 786-O, RCC4 and A498 cells were treated with different concentrations of 5-Aza-CdR. The results demonstrated that both mRNA and protein level of *KLF5* in these ccRCC cells were significantly and dose-dependently upregulated by 5-Aza-CdR (Figures 2D and E). Increasing levels in A498 cells were not as greatly as in 786-O and RCC4 cells, which might due to higher endogenous expression level of *KLF5* in A498 cells than that in 786-O and RCC4 cells. These results suggested hypermethylation might contribute to the downregulation of *KLF5* in ccRCC.

**Hypermethylation of *KLF5* is mainly maintained by DNMT1 in ccRCC.** DNA methylation is facilitated by three active enzymes, namely DNMT1, DNMT3A and DNMT3B. To determine which DNMTs contributed to *KLF5* hypermethylation




**Figure 1** *KLF5* expression is suppressed in ccRCC patients. (a) The heatmap showing the fold changes of mRNA expression levels of *KLF* family members compared ccRCC patients with normal people from the Oncomine, GEO and TCGA KIRC data sets. Arrow indicates relative change of *KLF5*. Oncomine data sets include: 1, Beroukhim renal; 2, Cutcliffe renal; 3, Gumz renal; 4, Jones renal; 5, Lenburg renal and 6, Yusenko renal. GSE53757 and GSE68417 are numbers of GEO data sets. (b) Boxplot of mRNA levels of *KLF5* in tissues of normal people ( $n = 72$ ) and ccRCC patients ( $n = 531$ ) from TCGA KIRC data sets. Two-tailed Student's *t*-test,  $P < 0.001$ . (c) Kaplan–Meier analysis of overall survival of ccRCC patients ( $n = 531$ ) segregated by low or high expression of *KLF5* from TCGA KIRC data sets. Log-rank test,  $P < 0.01$ . (d) Representative IHC staining images (left) and IRS scores (right) of *KLF5* expression of tumor or adjacent normal tissues from ccRCC patients ( $n = 13$ ). Scale bar, 50  $\mu\text{m}$ . Student's *t*-test,  $P < 0.001$ . (e) qPCR (up) and western blots (down) for the mRNA and protein levels of *KLF5* of indicated ccRCC and HEK-293T cells. Expression levels of *KLF5* in ccRCC cells were normalized to that in HEK-293T cells

in ccRCC, ShRNAs specifically against DNMT1, 3A and 3B were stably infected into 786-O, RCC4 and A498 cells separately. Compared with control ShRNA (ShCon) expressing 786-O cells, DNMT1 knockdown significantly increased *KLF5* expression both in mRNA and protein level, while DNMT3A knockdown had no effect on *KLF5* expression and DNMT3B knockdown slightly increased *KLF5* expression (Figures 3a and b). Whether DNMT1 could influence methylation levels of *KLF5* was then examined. Genomic DNA of ShCon and ShDNMT1 expressing 786-O cells were extracted and bisulfite sequencing was used to examine the methylation levels of high-methylated area as described in Figure 2C. Compared


with ShCon-expressing 786-O cells, knockdown of DNMT1 decreased *KLF5* methylation levels in high-methylated area (Figure 3c). This indicated that hypermethylation of *KLF5*, which suppressed its expression, was mainly maintained by DNMT1 in ccRCC. Consistent with the impact of DNMT1 on *KLF5* expression in 786-O cells, negative correlation of DNMT1 on *KLF5* expression were also evident in RCC4 and A498 cells (Figure 3d; Supplementary Figure 3A). It has been illustrated that 5-Aza-CdR is a DNA methylation inhibitor which leads to ubiquitin-dependent proteasome degradation of DNMT1.<sup>27,28</sup> To investigate whether 5-Aza-CdR-induced DNMT1 degradation contributed to *KLF5* upregulation in ccRCC, DNMTs

expression were detected in 786-O, RCC4 and A498 cells with or without 5-Aza-CdR treatment. 5-Aza-CdR treatment significantly decreased DNMT1 protein level rather than DNMT3A and DNMT3B levels in ccRCC cells (Figure 3e; Supplementary

Figure 3B). It has been described previously that DNMTs were overexpressed in ccRCC patients. Then, DNMTs expression were analyzed in TCGA KIRC data sets. Indeed, all of these DNMTs were highly expressed in ccRCC patients



**Figure 2** Hypermethylation suppresses *KLF5* expression in ccRCC. (A) A diagram represents methylation levels-altered CpG loci in *KLF5* gene of TCGA KIRC methylation array. Green box, arrow and lines indicates exons of *KLF5* gene, transcriptional start site and methylated loci (a–k) separately. (B) Methylation values of each indicated locus (a–k) in (A) were shown. Wilcoxon signed-rank test,  $P < 0.001$ . (C) 786-O cells were treated with DMSO or 5-Aza-CdR (10  $\mu$ M), then bisulfite sequencing (down) was utilized to measure the methylation levels of the diagram indicated loci (up) in low (1–4) and high (1–16)-methylated areas. Open circles ( $\circ$ ), unmethylated cytosine; closed circles ( $\bullet$ ), methylated cytosine. Sites 2/4 (d/e) in low-methylated area (1–4) and sites 2/4/11 (i/j/k) in high-methylated area (1–16) were known methylated loci from TCGA analyses. (D, E) qPCR and western blots for mRNA (D) and protein (E) level of *KLF5* in indicated ccRCC cell lines with or without 5-Aza-CdR treatment. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  by two-tailed Student's *t*-test. All bar graphs are plotted as mean  $\pm$  S.D. Expression level of *KLF5* was normalized to its internal control, which in 5-Aza-CdR-treated ccRCC cells were compared with that in non-treated cells




**Figure 3** Hypermethylation of *KLF5* gene is mainly maintained by DNMT1. (a,b) 786-O cells were infected with ShDNMTs or ShControl (ShCon) lentivirus, then qPCR (a) and western blots (b) were applied to detect mRNA and protein levels of *KLF5* and DNMTs. (c) Bisulfite sequencing (down) was applied to analyze the methylation levels of diagram-indicated loci (up) in high-methylated areas (1–16). Open circles (○), unmethylated cytosine; closed circles (●), methylated cytosine. (d) Western blots were utilized to detect expression of *KLF5* in ShDNMT1 or ShCon-expressing RCC4 or A498 cells. Quantity One software was used to normalize *KLF5* expression. Expression level of *KLF5* was normalized to its internal control, and relative expression of *KLF5* in ShDNMTs-expressed ccRCC cells were compared with that in ShCon-expressed cells. (e) Western blots for expression of DNMT1 in indicated ccRCC cell lines with or without 5-Aza-CdR treatment. (f) Scatter plots for the inverse correlation of *KLF5* with DNMT1 expression in ccRCC patients ( $n = 652$ ) from online TumourProfile database. Spearman rank correlation test,  $R_s =$  Spearman rank correlation coefficient. All bar graphs are plotted as mean  $\pm$  S.D. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  by two-tailed Student's *t*-test

compared with normal people (Supplementary Figures 3C and D). Furthermore, the correlations between *KLF5* and DNMTs expression were analyzed in 656 ccRCC samples from online TumourProfile database. Spearman rank correlation coefficient ( $R_s$ ) of these samples showed the inverse correlation between *KLF5* and DNMT1 expression in ccRCC (Figure 3f). Meanwhile, *KLF5* had weaker correlation with DNMT3B expression than with DNMT1 but had no correlation

with DNMT3A (Supplementary Figure 3E), which consistent with our *in vitro* results. In brief, our findings demonstrated that hypermethylation of *KLF5* was mainly maintained by DNMT1.

***KLF5* inhibits ccRCC cell proliferation and migration/invasion *in vitro*.** Abundant evidences have demonstrated critical roles of *KLF5* in regulating cell proliferation and migration/invasion in various cancers. Herein, we showed




**Figure 4** KLF5 inhibits ccRCC cell growth and migration/invasion *in vitro*. 786-O, A498 and RCC4 cells were stably infected with control (NC) or KLF5 lentivirus. (a) Western blots for KLF5 expression (left) and CCK8 analysis for proliferation (right) of indicated cells. (b) Representative colony formation of NC or KLF5-transduced 786-O, A498 and RCC4 cells (up) and statistical analyses of colony numbers (down). (c,d) Representative images of transwell migration (c) or invasion (d) assays of NC or KLF5-transduced 786-O, A498 and RCC4 cells (up) and statistical analyses of migrated or invaded cell numbers were shown (down). All experiments were repeated at least three times with triplicate samples. All bar graphs are plotted as mean  $\pm$  S.D. *P*-values are calculated between linked groups. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001

KLF5 expression was repressed by hypermethylation. This indicated KLF5 might be a tumor suppressor in ccRCC. To investigate the functional roles of KLF5 in ccRCC, KLF5 was overexpressed (OE) in 786-O, A498 and RCC4 ccRCC cell lines respectively. Ectopic expression of KLF5 effectively inhibited cell growth of these three cells (Figure 4a). Furthermore, colony formation ability of cells overexpressing KLF5 was markedly decreased in all of these three cell lines compared with related control cells (Figure 4b). Next, roles of KLF5 in ccRCC cells migration and invasion were evaluated.

KLF5 overexpression could not only distinctly suppress transwell migration ability of 786-O, A498 and RCC4 cells (Figure 4c), but also restrain their invasion capacity (Figure 4d). Taken together, these data suggested KLF5 negatively associated with cell proliferation and migration/invasion in ccRCC cells.

**KLF5 expression suppresses ccRCC xenograft growth.**

Given that ectopic KLF5 expression inhibited ccRCC cell growth *in vitro*, whether KLF5 also affected tumor growth




**Figure 5** KLF5 expression inhibits ccRCC xenograft growth *in vivo*. NC or KLF5-transduced 786-O cells were inoculated subcutaneously into nude mice. (a) Tumor volumes were measured every week and growth curves of two groups were shown. (b–e) Images of euthanized mice (b) and excised tumors (c) were shown. Bodyweight with tumor (d) and tumor weight alone (e) were measured. (f–i) Representative images of H&E staining (f) or IHC staining of KLF5 or Ki-67 (g) of these tumors were shown. Scale bar, 50  $\mu$ m. Image J software was used to quantify the intensity of KLF5 (h) or Ki-67 positive cells (i) between NC and KLF5-transduced 786-O subcutaneous tumors. All bar graphs are plotted as mean  $\pm$  S.D. *P*-values are calculated between linked groups. \**P* < 0.05; \*\**P* < 0.01; \*\*\**P* < 0.001

*in vivo* was further investigated. To this end, 786-O cells expressing KLF5 or control vector (NC) were subcutaneously injected in flanks of BALB/c nude mice. Consistent with the anti-proliferation effects in ccRCC cell lines, tumor growth of 786-O xenograft was significantly impaired accompanied with KLF5 expression (Figures 5a–c). Compared with mice burdened 786-O-NC xenograft, mice bearing 786-O-KLF5-expressing tumor had higher bodyweight and dramatically smaller tumor volume and tumor weight (Figures 5d and e). Furthermore, the histological morphology of ccRCC, which the malignant cells were surrounded by dense vascular endothelial cells and characterized with clear cytoplasm arranged in nests or acinar structures, was apparently improved in xenograft overexpressing KLF5 (Figure 5f). Immunohistochemistry (IHC) staining showed that high

KLF5 staining was correlated with weak Ki-67 staining, and vice versa (Figures 5g–i). Together, these findings strongly indicated ectopic expression of KLF5 could significantly inhibited ccRCC growth *in vivo*.

**KLF5 expression inhibits ccRCC tumor metastasis.**

Metastasis, a major cause of most cancer-related deaths, is a feature of malignant tumors.<sup>29</sup> In Figures 4c and d, we showed that ectopic KLF5 expression inhibited ccRCC cell lines migration/invasion *in vitro*. To assess whether KLF5 could regulate tumor metastasis *in vivo*, 786-O control and OE KLF5 cells were infected with GFP-Luc separately (Figure 6a) and then retro-orbital venous plexus injected into nude mice. At week 12, all mice were euthanized and bioluminescence imaging (BLI) signal intensity of lungs from




**Figure 6** KLF5 expression suppresses ccRCC metastasis *in vivo*. GFP-luciferase (GFP-Luc) lentivirus was infected into NC and KLF5-transduced 786-O cells. These cells were then intravenously injected into nude mice. (a) Western blots were applied to detect expression of KLF5 in GFP-Luc cells. (b–i) Twelve weeks after injection, these mice were euthanized, and BLI images (b) and quantification of photon fluxes (c) or fluorescence images (d) and quantification of fluorescence fluxes (e) or images (f) of lungs were shown and compared. Black arrows in (f) indicated the metastatic nodules. Images at right are magnified view of yellow line circled images at left. The number of macroscopic lung metastasis nodules (g) and lung weight (h) were counted and compared. (i) Representative images of H&E staining of lung metastasis nodules (rounded by yellow lines) were shown. Scale bar, 50  $\mu$ m. All bar graphs are plotted as mean  $\pm$  S.D. \* $P$  < 0.05; \*\* $P$  < 0.01; \*\*\* $P$  < 0.001 by two-tailed Student's *t*-test

both group were detected. As displayed in Figures 6b and c, photon fluxes of lungs with KLF5-expressing tumor nodules decreased compared with that in control group. Consistently, fluorescence fluxes of lungs bearing KLF5-expressing tumors also decreased obviously (Figures 6d and e). Further histological analyses indicated KLF5 expression reduced the number of metastatic nodules and lung weight, which was consistent with the BLI signal intensity detected *in vivo* (Figures 6f–h). Representative hematoxylin-eosin (H&E) staining exhibited KLF5 expression inhibited the formation of metastatic colonies in lungs (Figure 6i). Therefore, these studies demonstrated KLF5 could effectively suppress the metastatic properties of ccRCC *in vivo*.

**5-Aza-CdR inhibits ccRCC cell proliferation through demethylation of KLF5.** Since hypermethylation of *KLF5* suppressed its expression and ectopic KLF5 could inhibit ccRCC growth both *in vitro* and *in vivo*, it is very interesting to evaluate whether upregulating endogenous KLF5 expression by demethylation of *KLF5* gene could inhibit cell growth. To this purpose, 786-O and A498 cells were stably infected with a ShRNA specifically against KLF5 (Figure 7a). Then cells expressing ShControl or ShKLF5 were treated with or without 5-Aza-CdR for 4 days, and proliferation of cells was measured every day. Accompanied by the upregulation of KLF5, 5-Aza-CdR treatment significantly inhibited cell growth of 786-O cells, and knockdown KLF5 by ShRNA could dramatically attenuate





**Figure 7** 5-Aza-CdR inhibits ccRCC cell proliferation partially by demethylation of *KLF5*. (a-d) ShControl (ShCon) or ShKLF5 were stably expressed in 786-O or A498 cells, then cells were treated with or without 5-Aza-CdR (1  $\mu M$  for 786-O cells and 10  $\mu M$  for A498 cells) for 4 days. Western blots for DNMT1 and *KLF5* expression (a and c) and CCK8 assay for cell proliferation (b and d) of these cells were shown. Cell growth curves were separately compared between ShCon with and without 5-Aza-CdR treatment or between ShCon and ShKLF5 with and without 5-Aza-CdR treatment. The statistical significance was indicated by *P*-value. (e-f) 786-O (e) or A498 cells (f) expressing ShCon and ShKLF5 were treated with different concentrations of 5-Aza-CdR and  $IC_{50}$  were calculated by GraphPad Prism 6.0 software. All experiments were repeated at least three times with triplicate samples. All bar graphs are plotted as mean  $\pm$  S.D. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  by two-tailed Student's *t*-test

5-Aza-CdR-induced growth inhibition (Figure 7b). Similar results also could be observed in A498 cells (Figures 7c and d), even though the effect was not as significant as in 786-O cells. These results indicated that *KLF5* mediated 5-Aza-CdR-induced growth inhibition of ccRCC cells. Furthermore, ShKLF5 or ShCon-expressing 786-O or A498 cells were exposed to different doses of 5-Aza-CdR. As showed in Figures 7e and f, cells expressing ShKLF5 endowed higher concentration of 5-Aza-CdR treatment than those ShCon-expressing ccRCC cells, which suggested that *KLF5* expression contributed to the growth inhibition of 5-Aza-CdR.

## Discussion

The roles of *KLF5* in tumorigenesis are due to its cellular and genetic context. In this study, our data evidence that *KLF5* is a

tumor suppressor in ccRCC based on the following facts: first, *KLF5* expression is inhibited in ccRCC patients no matter through database analysis or clinical patient samples histochemical staining, and patients with high expression of *KLF5* have better prognostic outcome; second, *KLF5* expression is suppressed by DNMT1-maintained genomic hypermethylation, and ectopic expression of *KLF5* inhibits ccRCC cells proliferation and migration/invasion *in vitro* and xenograft growth and metastasis *in vivo*; last but not least, DNMTs' inhibitor 5-Aza-CdR can restore *KLF5* expression and suppress ccRCC cell growth, while knockdown *KLF5* can decrease drug sensitivity to 5-Aza-CdR and abolish 5-Aza-CdR-induced cell growth inhibition.

In mammals, DNA methylation is present predominantly in the context of CpG dinucleotides and is involved in regulation of chromatin structure and gene expression.

Hypermethylation of promoter or enhancer can result in inactivation of important tumor suppressor genes whereas hypomethylation of genomic DNA is associated with chromosomal instability and tumorigenesis.<sup>30–32</sup> DNA methylation is mediated by a family of enzymes named DNMTs. To date, the known DNMTs are DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L. Methylation can be *de novo* methylation of CpG dinucleotides on totally unmethylated DNA strands or maintenance methylation of CpG dinucleotides on DNA that one strand has been methylated. DNMT1 has both *de novo* and maintenance methyltransferase activity, while DNMT3A and DNMT3B are powerful *de novo* methyltransferases. DNMT2 is shown to methylate RNA and DNMT3L does not have methyltransferase activity.<sup>8</sup> Previous studies have showed hypermethylation of *KLF5* in intron 1 that downregulated *KLF5* expression might correlated with DNMT3A mutation in AML.<sup>21,33,34</sup> In this study, we found that *KLF5* expression was also suppressed by hypermethylation, but the methylated loci reported in AML, including that in proximal promoter (–529 to –318 bp from transcription start site (TSS)) and in intron 1 (+1284 to +1571 bp from TSS), could not be found in ccRCC. Although DNMT3A might contribute to the hypermethylation of *KLF5* in AML, knockdown of DNMT3A could not restore *KLF5* expression in ccRCC cells, but inhibition of DNMT1 could. Online data sets analyses indicated that DNMT3B expression was slightly correlated with *KLF5* expression in ccRCC. When knockdown DNMT3B, *KLF5* expression was upregulated weakly. Whether DNMT3B contributes to the *de novo* methylation of *KLF5* in ccRCC remains to be elucidated. The presence of increased methylation level of eleven methylated loci of *KLF5* in ccRCC patients indicated dysregulation of methylation at *KLF5* genome by TCGA analyses. Surprisingly, we first observed that hypermethylated loci of *KLF5* located at proximal exon 4 in ccRCC. When treated with 5-Aza-CdR or knockdown DNMT1 expression, methylation levels of ccRCC cells at proximal exon 4 area were decreased. These findings indicated that hypermethylated loci at proximal exon 4 area, which were far away from *KLF5* TSS, could affect *KLF5* expression in ccRCC. The mechanisms why DNA hypermethylation is present at proximal exon 4 in ccRCC and how DNMT1 regulates *KLF5* hypermethylation remain to be explored. The current view of DNA methylation indicates that the correlation between CpG methylation and gene expression depends on genomic context. CpGs locate both in gene regulatory regions, which are less than 2 kb away from the TSS, and in the gene bodies, which are more than 2 kb away from the TSS. Methylation of CpGs at gene regulatory regions is negatively correlated with gene expression, while methylation of CpGs at gene bodies be either positively or negatively correlated with gene expression. When CpGs locate at gene bodies but do not reside in a CpG island (CGI), methylation of CpGs is positively correlated with gene expression. When CpGs locate at gene bodies and also reside in a CGI, methylation is negatively correlated with gene expression. What's more, the CpG-rich regions in the gene bodies whose methylation is negatively correlated with gene expression might be intragenic enhancers.<sup>35</sup> Whether the methylation loci we found is an intragenic enhancer of *KLF5* gene remains to be elucidated.

Due to various cellular and genetic context, *KLF5* has exerted pro- or anti-tumorigenic function in different types of tumors. In our study, *KLF5* functions as a tumor suppressor in ccRCC. It has been found that acetylation of *KLF5* influenced its roles in tumor and interruption *KLF5* acetylation could reverse its role from a tumor suppressor to a tumor promoter.<sup>36,37</sup> Whether acetylation of *KLF5* involves in the tumorigenesis of ccRCC remains to be investigated. Xing *et al.* demonstrated that *KLF5* deletion in *PTEN*-null mice upregulated epidermal growth factor (EGF) and its downstream signaling molecules AKT and ERK and initiated luminal-type mouse prostate tumors.<sup>38</sup> It has been reported that tumor suppressor gene *PTEN* was deleted or mutated during ccRCC carcinogenesis.<sup>7,39</sup> *KLF5* also could inhibit the activation of ERK in ccRCC (data not shown). These findings indicated that *KLF5*-ERK axis might regulate cell growth in ccRCC. Zhang *et al.* reported that *KLF5* could inhibit epithelial-mesenchymal transition (EMT) through activation microRNA200 expression.<sup>40</sup> Whether *KLF5* inhibits ccRCC metastasis mediated by microRNAs deserves to be deeply explored. The underlying mechanisms that how *KLF5* has a tumor suppressor role in ccRCC need to be further studied.

Despite the epigenetic regulation of *KLF5* in ccRCC, post-translational regulation of *KLF5*, especially protein stability, was also been considered. It has been reported that *KLF5* was degraded by ubiquitin-proteasome pathway (UPP). At present, several E3 ligases, including WWP1,<sup>41</sup> EFP,<sup>42</sup> Smurf2<sup>43</sup> and FBW7,<sup>44</sup> were discovered to ubiquitinate *KLF5* which led to its degradation. MG132, a 26 S proteasome inhibitor, was used to treat ccRCC cells. *KLF5* protein was stabilized by MG132 treatment, especially in A498 cells (Supplementary Figure 4). Thus, protein instability was also contributed to the low level of *KLF5* in ccRCC cells. In addition, *KLF5* can be stabilized by the deubiquitinase (DUB) BAP1,<sup>45</sup> and *BAP1* gene is inactivated in 15% ccRCC and defines a new class of ccRCC.<sup>46</sup> Inactivation of deubiquitinases and over-activation of E3 ligases might be post-translational mechanism for the suppression of *KLF5* in ccRCC.

In this study, we demonstrated that *KLF5*, as a tumor suppressor, was suppressed by DNMT1-maintained hypermethylation in ccRCC. DNMTs' inhibitor 5-Aza-CdR could suppress ccRCC cell growth and induce *KLF5* expression, and *KLF5* mediated 5-Aza-CdR-induced growth inhibition. Collectively, our research highlights the potential of 5-Aza-CdR, a methylation inhibitor that can rescue *KLF5* expression, as a therapeutic modality for the treatment of ccRCC.

## Materials and Methods

**Cell lines and reagents.** Human ccRCC cell lines 786-O, RCC4, A498, Caki-1 and immortal embryonic kidney cell line HEK-293T were obtained from the cell bank of the Chinese Academy of Sciences (Shanghai, China). RCC4, A498 and HEK-293T cells were cultured in Dulbecco's modified Eagle's medium (Hyclone, Logan, UT, USA) with 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO, USA). 786-O and Caki-1 cells were maintained in RPMI 1640 (Hyclone) with 10% FBS. All cells were cultured in a 95% air and 5% CO<sub>2</sub> humidified atmosphere at 37 °C. 5-Aza-CdR (Sigma-Aldrich, A3656) was dissolved in DMSO as stocking solution and diluted in sterile PBS before use.

**Patient cohort.** Paired specimens of tumor and adjacent tissues of ccRCC patients ( $n = 13$ ), which were histopathologically diagnosed during 2015 and 2016, were obtained in Ren-Ji Hospital affiliated to Shanghai Jiao Tong University School

of Medicine. All samples were primary tumors and untreated before surgery. Detailed information was described in the Supplementary Table 1. These studies were approved by the Medical Ethical Committee of Ren-Ji Hospital, and informed consent was obtained from all subjects or their relatives.

**Immunohistochemical staining.** IHC was applied to detect the protein levels of KLF5 between ccRCC tumors and adjacent normal tissues with anti-KLF5 (Sigma-Aldrich, HPA040398) polyclonal antibody. IHC staining was performed according to the manufacturer's protocol. All staining were blindly scored by two pathologists according to the intensity of the nucleus, cytoplasmic and/or membrane staining (no staining = 0; weak staining = 1, moderate staining = 2, strong staining = 3) and the area extent of stained cells (0% = 0, 1–24% = 1, 25–49% = 2, 50–74% = 3, 75–100% = 4). The final immunoreactive score (IRS) was determined by multiplying the intensity score with the extent score of stained cells, ranging from 0 (the minimum score) to 12 (the maximum score). Final scores of KLF5 between thirteen pairs of ccRCC patients and normal adjacent tissues were calculated by GraphPad Prism 6.0 software. IHC staining of KLF5 and Ki-67 for 786-O xenograft were performed with anti-KLF5 and anti-Ki-67 (Abcam, Cambridge, MA, USA, ab16667) polyclonal antibody. The intensity of KLF5 and Ki-67 positive cells were quantified by Image J software.

**Plasmids, ShRNA design and viral infection.** Human *KLF5* cDNA was cloned and inserted into pLVX-Puromycin lentiviral expression vector (Clontech, CA, USA). GV298-CMV-mU6-MSC-Cherry-Puromycin lentiviral plasmid expressing ShKLF5 and control plasmid were purchased from GENECHEM (Shanghai, China). The target sequence for ShKLF5 was shown in Supplementary Table 2. pGIRZ-hCMV-tGFP-Puromycin lentiviral plasmids against DNMTs DNMT1/3A/3B and control were obtained from department of biochemistry and molecular biology, Shanghai Jiao Tong University School of Medicine. The target sequences for ShDNMTs were shown in Supplementary Table 2. pBABE-puro-VHL-Flag and pSIREN-ShVHL plasmids were gifts from Prof. Li-Shun Wang (Central Hospital of Min Hang District, Shanghai, China). These plasmids were co-transfected with packaging plasmids including psPAX2 and pMD2G for lentivirus or VSVG and gag-pol for retrovirus into HEK-293T cells to produce lentivirus or retrovirus. Forty-eight hours after transfection, the viral supernatants were harvested, filtered through 0.45  $\mu$ m membrane (Merck-Millipore, MA, USA) and added respectively into 786-O, RCC4 and A498 cells incubated with the medium containing 0.8  $\mu$ g/ml polybrene (Santa Cruz Biotechnology, Texas, USA, sc-134220). Stably expressed cells were selected by 1  $\mu$ g/ml puromycin after viral infection for 48 h. Selection was stopped as soon as the non-infected control cells died off, and the media were replaced with normal growth media.

**Western blots.** Western blots was performed as described before.<sup>47</sup> Western blots images were acquired using the LAS-4000 CCD imaging system (Fujifilm, Japan). The following antibodies were used: Rabbit polyclonal antibodies against KLF5 (Proteintech Group, Rosemont, IL, USA, 21017-1-AP), VHL (Novus Biologicals, Littleton, CO, USA, NB100-485), DNMT1 (Cell Signaling Technology, Beverly, MA, USA, #5032), DNMT3A (Cell Signaling Technology, #D23G1), Mouse monoclonal antibody against DNMT3B (Santa Cruz Biotechnology, sc-376043), HRP-linked  $\beta$ -actin monoclonal antibody (Proteintech Group, HRP-60008) and HRP-linked  $\alpha$ -tubulin polyclonal antibody (MBL International Corporation, MA, USA, PM0547). The protein levels were quantified by Quantity One software.

**Quantitative real-time RT-PCR.** Total RNA was extracted by TriPure Isolation Reagent (Roche, Basel, Switzerland) and reverse transcription was carried out using M-MLV reverse transcriptase (Promega, Madison, WI, USA). QPCR of the target genes were carried out with Power SYBR Green PCR Master mix (Applied Biosystems, Foster City, CA, USA) using ABI PRISM 7900HT Fast system (Thermo Fisher Scientific, Waltham, MA, USA). Experiments were repeated at least three times with similar results. A list of qPCR primers could be found in Supplementary Table 3.

**Cell proliferation and colony formation assay.** Cells proliferation was evaluated by the CCK8 assay (WST-8; Cell counting kit-8 from Dojindo, Japan). Briefly, 100  $\mu$ l cells were seeded into 96-well plates at a density of 2000 cells/well. WST-8 was added and absorbance readings at a wavelength of 450 nm were taken on Synergy H4 Hybrid Microplate Reader (BioTek, Winooski, VT, USA). For colony formation assay, 600 cells for RCC4 and 1000 cells for 786-O or A498 were plated in complete growth media and allowed to grow until visible colonies formed. Cell

colonies were stained with 0.1% crystal violet and photographed. Total cell numbers were counted and calculated by GraphPad Prism 6.0 software (San Diego, CA, USA).

**Transwell migration and invasion assay.** For transwell migration assay using 786-O, RCC4 and A498 cells, twenty-five thousand cells were plated on 8- $\mu$ m transwell filters (Corning, NY, USA). For transwell invasion assay, fifty thousand cells were seeded and meanwhile, inserts were coated on the inside with Matrigel (BD Biosciences, San Jose, CA, USA). Cells in insert chambers, which were cultured with no FBS, migrated towards lower compartment that containing medium with FBS. Non-migration and invasion cells were removed with a cotton swab. The remaining cells were stained with crystal violet and photographed. Cells in fifteen random fields were counted under microscope and calculated by GraphPad Prism 6.0 software.

**Animal experiments.** Five million 786-O cells expressing KLF5 or control vector were subcutaneously injected into 6-week-old female BALB/c nude mice ( $n = 4$  for each group). Tumor was measured weekly and volume was calculated according to the following formula: volume = length  $\times$  width  $\times$  (width/2). At week 11, mice were euthanized and applied to further histological analysis. For lung metastasis assay, KLF5 or vector expressed 786-O cells were infected with GFP-Luc, then three million cells were injected into retro-orbital venous plexus of nude mice ( $n = 6$  for each group). For bioluminescence imaging (BLI), D-luciferin (YEASEN, Shanghai, China) was injected into anesthetized mice and bioluminescence images were captured (Xenogen IVIS, PerkinElmer, Waltham, MA, USA). At week 12, mice were euthanized and applied to further histological analysis. All measurements were performed blindly and all animals were manipulated and housed according to protocols approved by Shanghai Medical Experimental Animal Care Commission.

**Conventional bisulfite sequencing.** For bisulfite sequencing, extracted genomic DNA was bisulfite converted according to the manufacturer's instructions of an EZ DNA Methylation-Direct Kit (Zymo Research, CA, USA). Bisulfite-treated genomic DNA was subjected to PCR amplification. Primers used for detection methylation levels of *KLF5* gene in low-methylated and high-methylated area were shown in Supplementary Table 4. For further sequencing analysis, PCR products were purified with a Gel Extraction Kit (MACHEREY-NAGEL, Düren, Germany) and cloned into pMD19-T vectors (Takara, Kusatsu, Japan). Individual clones were sequenced and analyzed with original sequences by DNAMAN software.

**Cell viability assay and IC50 values.** To evaluate drug sensitivity of ccRCC cells to 5-Aza-CdR, 786-O or A498 cells were seeded in 96-well plates at a density of 4000 cells/well for 786-O and 3000 cells/well for A498. Cells were then exposed to different concentrations of 5-Aza-CdR for 48 h. Then, CCK8 reagent was added and cell growth was measured by the absorbance at wavelength of 450 nm. The half-maximal inhibitory concentration (IC50) values were calculated by nonlinear regression analysis using the GraphPad Prism 6.0 software.

**RNA-sequencing and Microarray data sets analysis.** Expression levels of *KLF5* were obtained from the Cancer Genome Atlas (TCGA), Oncomine and GEO respectively. TCGA clear cell kidney carcinoma (TCGA KIRC) data set portal (<https://tcga-data.nci.nih.gov/tcga/>) includes 72 normal people and 531 ccRCC patients. To segregate 531 patients according to high- or low-*KLF5* expression, the median expression was calculated. If *KLF5* expression was under the median value, patients were regarded as *KLF5*-low group, and *vice versa*. CpG DNA methylation array of TCGA KIRC data set was used to analyze methylation level of each *KLF5* CpG locus between KIRC patients and normal people. Six cohorts of ccRCC in Oncomine database (<http://www.oncomine.org>) were analyzed, and threshold was set as  $P < 0.05$  and fold change  $> 2$ . GSE53757 and GSE68417 were selected from GEO data sets. GEO2R (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) interactive web tool was used to compare different *KLF5* expression between normal people and ccRCC patients. Normalized gene expression values of 652 ccRCC from the TumourProfile database (<http://tumour.bjmu.edu.cn/>), whose original data were obtained from GEO, were downloaded and analyzed.

**Statistical analysis.** All the statistical analyses were evaluated using the GraphPad Prism 6.0 software. Each experiment was repeated at least three times. Data were presented as mean  $\pm$  S.D., and Student's *t*-test (unpaired, two-tailed) was used to compare two groups of independent samples. Kaplan–Meier method was used to analyze overall survival (OS) and comparisons were analyzed by log-rank test. Statistical significance of Spearman rank correlation coefficient (*R*s)

was determined by Spearman rank correlation test.  $P < 0.05$  was considered to be statistically significant.

### Conflict of Interest

The authors declare no conflict of interest.

**Acknowledgements.** This work was supported by the National Basic Research Program of China (973 Program, 2015CB910403 to G.C. and National Science Foundation of China (81572692 to K.Z., 81472461 to L.H.). The authors would like to thank Prof. Li-Shun Wang (Central Hospital of Min Hang District, Shanghai, China) for providing pBABE-puro-VHL-Flag and pSIREN-ShVHL plasmids, Dr. Huan-Yin Tang (Tong Ji University, Shanghai, China) for TCGA data analysis and Ms. Jing Zhou (Shanghai Jiao Tong University School of Medicine) for assistance in BLI imaging system.

- Riazalhosseini Y, Lathrop M. Precision medicine from the renal cancer genome. *Nat Rev Nephrol* 2016; **12**: 655–666.
- Cohen HT, McGovern FJ. Renal-cell carcinoma. *N Engl J Med* 2005; **353**: 2477–2490.
- Majer W, Kluzek K, Bluyssen H, Wesoly J. Potential approaches and recent advances in biomarker discovery in clear-cell renal cell carcinoma. *J Cancer* 2015; **6**: 1105–1113.
- Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ *et al*. Renal cell carcinoma guideline. *Eur Urol* 2007; **51**: 1502–1510.
- Rydzanicz M, Wrzesinski T, Bluyssen HA, Wesoly J. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. *Cancer Lett* 2013; **341**: 111–126.
- Das PM, Singal R. DNA methylation and cancer. *J Clin Oncol* 2004; **22**: 4632–4642.
- Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* 2013; **499**: 43–49.
- Fernandez AF, Huidobro C, Fraga MF. De novo DNA methyltransferases: oncogenes, tumor suppressors, or both? *Trends Genet* 2012; **28**: 474–479.
- Li M, Wang Y, Song Y, Bu R, Yin B, Fei X *et al*. Expression profiling and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic human renal cell carcinoma. *Int J Clin Exp Pathol* 2014; **7**: 7597–7609.
- Momparler RL. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). *Semin Hematol* 2005; **42**: S9–S16.
- Gore SD, Jones C, Kirkpatrick P. Decitabine. *Nat Rev Drug Discov* 2006; **5**: 891–892.
- Nie J, Liu L, Li X, Han W. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors. *Cancer Lett* 2014; **354**: 12–20.
- Hagiwara H, Sato H, Ohde Y, Takano Y, Seki T, Ariga T *et al*. 5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. *Br J Pharm* 2008; **153**: 1373–1381.
- Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D *et al*. Noncytotoxic differentiation treatment of renal cell cancer. *Cancer Res* 2011; **71**: 1431–1441.
- McConnell BB, Yang VW. Mammalian Krüppel-like factors in health and diseases. *Physiol Rev* 2010; **90**: 1337–1381.
- Tetreault MP, Yang Y, Katz JP. Krüppel-like factors in cancer. *Nat Rev Cancer* 2013; **13**: 701–713.
- Dong JT, Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. *Cell Mol Life Sci* 2009; **66**: 2691–2706.
- Jia L, Zhou Z, Liang H, Wu J, Shi P, Li F *et al*. KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. *Oncogene* 2016; **35**: 2040–2051.
- Gao Y, Wu K, Chen Y, Zhou J, Du C, Shi Q *et al*. Beyond proliferation: KLF5 promotes angiogenesis of bladder cancer through directly regulating VEGFA transcription. *Oncotarget* 2015; **6**: 43791–43805.
- Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. *Prostate* 2003; **55**: 81–88.
- Diakiw SM, Kok CH, To LB, Lewis ID, Brown AL, D'Andrea RJ. The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. *Leukemia Res* 2012; **36**: 110–116.
- Gao Y, Ding Y, Chen H, Chen H, Zhou J. Targeting Krüppel-like factor 5 (KLF5) for cancer therapy. *Curr Top Med Chem* 2015; **15**: 699–713.
- Diakiw SM, D'Andrea RJ, Brown AL. The double life of KLF5: Opposing roles in regulation of gene-expression, cellular function, and transformation. *JUBMB Life* 2013; **65**: 999–1011.
- Fujii K, Manabe I, Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. *J Clin Invest* 2011; **121**: 3425–3441.
- Chen WC, Lin HH, Tang MJ. Matrix-stiffness-regulated inverse expression of Krüppel-like factor 5 and Krüppel-like factor 4 in the pathogenesis of renal fibrosis. *Am J Pathol* 2015; **185**: 2468–2481.
- Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. *Nat Rev Cancer* 2015; **15**: 55–64.

- Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T *et al*. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. *Mol Cell Biol* 2005; **25**: 4727–4741.
- Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A *et al*. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. *Nat Genet* 2003; **33**: 61–65.
- Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. *Nat Med* 2013; **19**: 1450–1464.
- Hamidi T, Singh AK, Chen T. Genetic alterations of DNA methylation machinery in human diseases. *Epigenomics* 2015; **7**: 247–265.
- Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y *et al*. DNA methylation, its mediators and genome integrity. *Int J Biol Sci* 2015; **11**: 604–617.
- Hu CY, Mohlath D, Yu Y, Ko YA, Shenoy N, Bhattacharya S *et al*. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. *Clin Cancer Res* 2014; **20**: 4349–4360.
- Humbert M, Halter V, Shan D, Laedrach J, Leibundgut EO, Baerlocher GM *et al*. Deregulated expression of Krüppel-like factors in acute myeloid leukemia. *Leukemia Res* 2011; **35**: 909–913.
- Diakiw SM, Perugini M, Kok CH, Engler GA, Cummings N, To LB *et al*. Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. *Br J Haematol* 2013; **161**: 884–888.
- Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F *et al*. Dynamic DNA methylation across diverse human cell lines and tissues. *Genome Res* 2013; **23**: 555–567.
- Guo P, Zhao KW, Dong XY, Sun X, Dong JT. Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-beta-mediated induction in epithelial cells. *J Biol Chem* 2009; **284**: 18184–18193.
- Li X, Zhang B, Wu Q, Ci X, Zhao R, Zhang Z *et al*. Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. *Int J Cancer* 2015; **136**: 536–546.
- Xing C, Ci X, Sun X, Fu X, Zhang Z, Dong EN *et al*. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways. *Neoplasia* 2014; **16**: 883–899.
- Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. *Int J Cancer* 2002; **99**: 53–57.
- Zhang B, Zhang Z, Xia S, Xing C, Ci X, Li X *et al*. KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. *Mol Cell Biol* 2013; **33**: 4919–4935.
- Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X *et al*. Human Krüppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. *J Biol Chem* 2005; **280**: 41553–41561.
- Zhao KW, Sikriwal D, Dong X, Guo P, Sun X, Dong JT. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. *Biochem J* 2011; **437**: 323–333.
- Du JX, Hagos EG, Nandan MO, Bialkowska AB, Yu B, Yang VW. The E3 ubiquitin ligase SMAD ubiquitination regulatory factor 2 negatively regulates Krüppel-like factor 5 protein. *J Biol Chem* 2011; **286**: 40354–40364.
- Zhao D, Zheng HQ, Zhou Z, Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. *Cancer Res* 2010; **70**: 4728–4738.
- Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G *et al*. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. *Nat Commun* 2015; **6**: 8471.
- Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S *et al*. BAP1 loss defines a new class of renal cell carcinoma. *Nat Genet* 2012; **44**: 751–759.
- Zhao X-Y, Li L, Wang X-B, Fu R-J, Lv Y-P, Jin W *et al*. Inhibition of Snail family transcriptional repressor 2 (SNAIL2) enhances multidrug resistance of hepatocellular carcinoma cells. *PLoS One* 2016; **11**: e0164752.



**Cell Death and Disease** is an open-access journal published by **Nature Publishing Group**. This work is licensed under a **Creative Commons Attribution 4.0 International License**. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017

Supplementary Information accompanies this paper on Cell Death and Disease website (<http://www.nature.com/cddis>)